High-dose chemotherapy with autologous marrow transplantation for malignant melanoma: Case reports and literature review

Anne Kessinger

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Present-day therapy for disseminated malignant melanoma is unsatisfactory; chemotherapy offers a small fraction of patients a short-lived palliative effect. Evidence exists to suggest more responses to chemotherapy could occur if dosages of chemotherapeutic agents were increased. The dosages of many chemotherapeutic agents used for melanoma are limited by myelotoxicity of the drugs. Autologous bone marrow transplantation offers a means to escalate chemotherapeutic dosages by shortening the period of life-threatening marrow toxicity to a survivable length of time. A review of 103 cases of melanoma treated with high-dose chemotherapy and autologous marrow rescue plus two cases reported here revealed that 48% of patients responded to therapy and 34% of those were complete responses. The exact role this technic will play in management of disseminated malignant melanoma requires further study.

Original languageEnglish (US)
Pages (from-to)337-343
Number of pages7
JournalJournal of the American Academy of Dermatology
Volume12
Issue number2
DOIs
StatePublished - Jan 1 1985

Fingerprint

Autologous Transplantation
Melanoma
Bone Marrow
Drug Therapy
Bone Marrow Transplantation
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Dermatology

Cite this

High-dose chemotherapy with autologous marrow transplantation for malignant melanoma : Case reports and literature review. / Kessinger, Anne.

In: Journal of the American Academy of Dermatology, Vol. 12, No. 2, 01.01.1985, p. 337-343.

Research output: Contribution to journalArticle

@article{7aaf7bcb7db04bd186d19dc607a706ca,
title = "High-dose chemotherapy with autologous marrow transplantation for malignant melanoma: Case reports and literature review",
abstract = "Present-day therapy for disseminated malignant melanoma is unsatisfactory; chemotherapy offers a small fraction of patients a short-lived palliative effect. Evidence exists to suggest more responses to chemotherapy could occur if dosages of chemotherapeutic agents were increased. The dosages of many chemotherapeutic agents used for melanoma are limited by myelotoxicity of the drugs. Autologous bone marrow transplantation offers a means to escalate chemotherapeutic dosages by shortening the period of life-threatening marrow toxicity to a survivable length of time. A review of 103 cases of melanoma treated with high-dose chemotherapy and autologous marrow rescue plus two cases reported here revealed that 48{\%} of patients responded to therapy and 34{\%} of those were complete responses. The exact role this technic will play in management of disseminated malignant melanoma requires further study.",
author = "Anne Kessinger",
year = "1985",
month = "1",
day = "1",
doi = "10.1016/S0190-9622(85)80049-9",
language = "English (US)",
volume = "12",
pages = "337--343",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - High-dose chemotherapy with autologous marrow transplantation for malignant melanoma

T2 - Case reports and literature review

AU - Kessinger, Anne

PY - 1985/1/1

Y1 - 1985/1/1

N2 - Present-day therapy for disseminated malignant melanoma is unsatisfactory; chemotherapy offers a small fraction of patients a short-lived palliative effect. Evidence exists to suggest more responses to chemotherapy could occur if dosages of chemotherapeutic agents were increased. The dosages of many chemotherapeutic agents used for melanoma are limited by myelotoxicity of the drugs. Autologous bone marrow transplantation offers a means to escalate chemotherapeutic dosages by shortening the period of life-threatening marrow toxicity to a survivable length of time. A review of 103 cases of melanoma treated with high-dose chemotherapy and autologous marrow rescue plus two cases reported here revealed that 48% of patients responded to therapy and 34% of those were complete responses. The exact role this technic will play in management of disseminated malignant melanoma requires further study.

AB - Present-day therapy for disseminated malignant melanoma is unsatisfactory; chemotherapy offers a small fraction of patients a short-lived palliative effect. Evidence exists to suggest more responses to chemotherapy could occur if dosages of chemotherapeutic agents were increased. The dosages of many chemotherapeutic agents used for melanoma are limited by myelotoxicity of the drugs. Autologous bone marrow transplantation offers a means to escalate chemotherapeutic dosages by shortening the period of life-threatening marrow toxicity to a survivable length of time. A review of 103 cases of melanoma treated with high-dose chemotherapy and autologous marrow rescue plus two cases reported here revealed that 48% of patients responded to therapy and 34% of those were complete responses. The exact role this technic will play in management of disseminated malignant melanoma requires further study.

UR - http://www.scopus.com/inward/record.url?scp=0021947193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021947193&partnerID=8YFLogxK

U2 - 10.1016/S0190-9622(85)80049-9

DO - 10.1016/S0190-9622(85)80049-9

M3 - Article

C2 - 3882786

AN - SCOPUS:0021947193

VL - 12

SP - 337

EP - 343

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 2

ER -